Board of Directors
Seth L. Harrison, M.D.
Chairman, Tokai Pharmaceuticals, Inc.
Managing General Partner, Apple Tree Partners
Prior Affiliations: Oak Investment Partners, Sevin Rosen Funds
Reinhard J. Ambros, Ph.D.
Executive Director, Novartis Venture Fund
Prior Affiliations: Novartis Corporate Finance, Novartis Pharma, Roche
Timothy J. Barberich
Prior Affiliations: Sepracor Inc., Millipore Corporation
David A. Kessler, M.D.
Professor, University of California San Francisco
Prior Affiliations: FDA (Commissioner),Yale Medical School (Dean), University of California, San Francisco School of Medicine (Dean)
President and Chief Executive Officer, Tokai Pharmaceuticals, Inc.
Prior Affiliations: Dyax Corporation, Curis, Inc. and Diacrin, Inc.
Campbell Murray, M.D.
Managing Director, Novartis Venture Fund
Prior Affiliations: Novartis Institutes for BioMedical Research, Auckland Hospital and Middlemore Hospital
Joseph A. Yanchik III, Esq.
President and CEO, Aileron Therapeutics, Inc.
Prior Affiliations: Tokai Pharmaceuticals, Mendel Biotechnology, Poetic Genetics, Venture Law Group, Cahill Gordon & Reindel